TCIM
RARX
TIAA CREF Investment Management’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q1 | $6.79M | Sell |
303,258
-380,737
| -56% | -$8.53M | ﹤0.01% | 1262 |
|
|
2018
Q4 | $12.4M | Buy |
683,995
+403,234
| +144% | +$7.34M | 0.01% | 852 |
|
|
2018
Q3 | $5.08M | Buy |
280,761
+208,720
| +290% | +$3.78M | ﹤0.01% | 1558 |
|
|
2018
Q2 | $717K | Buy |
72,041
+26,600
| +59% | +$265K | ﹤0.01% | 2633 |
|
|
2018
Q1 | $241K | Buy |
45,441
+16,147
| +55% | +$85.6K | ﹤0.01% | 2951 |
|
|
2017
Q4 | $249K | Sell |
29,294
-1,977
| -6% | -$16.8K | ﹤0.01% | 2978 |
|
|
2017
Q3 | $457K | Hold |
31,271
| – | – | ﹤0.01% | 2864 |
|
|
2017
Q2 | $586K | Buy |
31,271
+23,434
| +299% | +$439K | ﹤0.01% | 2789 |
|
|
2017
Q1 | $167K | Buy |
7,837
+3,859
| +97% | +$82.2K | ﹤0.01% | 3015 |
|
|
2016
Q4 | $60K | Buy |
+3,978
| New | +$60K | ﹤0.01% | 3100 |
|